Overview

An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled Asthma

Status:
Terminated
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The study proposes to evaluate the safety and efficacy of PF-03715455 in moderate to severe asthma when added to standard of care and during staged withdrawal of background therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer